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Introduction: Functional mobility (FM) is a concept that incorporates the capacity of a
person to move independently and safely to accomplish tasks. It has been proposed as
a Parkinson’s disease (PD) functional and global health outcome. In this study, we aimed
to identify which kinematic and clinical outcomes changes better predict FM changes
when PD patients are submitted to a specialized multidisciplinary program.
Methods: PD patients engaged in a pre-defined specialized multidisciplinary program
were assessed at admission and discharge. Change from baseline was calculated for
all kinematic and clinical outcomes, and Timed Up and Go (TUG) was defined as the
primary outcome for FM. A stepwise multivariate linear regression was performed to
identify which outcome measures better predict TUG changes.
Results: Twenty-four patients were included in the study. The changes in TUG Cognitive
test, supervised step length, and free-living (FL) step time asymmetry were identified
as the best predictors of TUG changes. The supervised step length and FL step time
asymmetry were able to detect a small to moderate effect of the intervention (d values
ranging from −0.26 to 0.42).
Conclusions: Our results support the use of kinematic outcome measures to evaluate
the efficacy of multidisciplinary interventions on PD FM. The TUG Cognitive, step length,
and FL step time asymmetry were identified as having the ability to predict TUG changes.
More studies are needed to identify the minimal clinically important difference for step
length and FL step time asymmetry in response to a multidisciplinary intervention for
PD FM.
Keywords: Parkinson’s disease, functional mobility, outcome measures, gait, sensors, digital health, wearable,
technology
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INTRODUCTION
Functional mobility (FM) in Parkinson’s disease (PD) has been
recently described as a person’s physiological ability to move
independently and safely in a variety of environments in order
to accomplish functional activities or tasks and to participate
in activities of daily living at home, at work, and in the
community (1, 2). From the early disease stage, PD patients
experience limitations in their FM. With disease progression,
these limitations are usually a major cause of disability and loss
of independence (1).
FM has been reported as a useful outcome measure to
understand patients’ overall health status, to address their daily
needs related to mobility and social participation, and for
monitoring, in a closer and more realistic fashion, the impact
of disease progression and the effect of therapeutic interventions
(2–4). The Timed Up and Go (TUG) test is a quick and easy-
to-use test, specifically designed to measure FM that includes
the three anchors of the concept, i.e., gait, balance, and postural
transitions (2, 4, 5). Although it is the recommended tool for
assessing FM in PD, other clinical tests are also used (2, 4, 5).
The development of technology-based objective measures
(TOMs) and the possibility of using accurate and reliable
quantitative information to evaluate PD patients’ gait enable
a more objective and ecological (i.e., closer to patients’ real-
life environment performance) perspective of patients’ FM
(6, 7). A recent systematic review on outcome measures for
assessing FM in PD included nine studies using kinematic gait
parameters (2). The authors emphasize the important role of
TOMs in monitoring FM throughout disease progression. They
also highlight that despite the capacity of current devices to
capture large amounts of data and a great diversity of parameters,
the best kinematic parameters for assessing FM in PD remain to
be defined (2).
In this study, we aimed to identify which kinematic
and clinical outcome measures better predict FM




A pragmatic prospective clinical study was conducted.
Objective
The objective of this study is to identify the kinematic
and clinical outcome measures that better predict FM
changes when PD patients are submitted to a specialized
multidisciplinary intervention.
Participants
Study participants were recruited from CNS—Campus
Neurológico, a tertiary specialized movement disorders
center in Portugal. Patients were eligible if they had a diagnosis
of probable or clinically established PD (according to the
International Parkinson and Movement Disorder Society
criteria), had engaged in the specialized multidisciplinary
program for parkinsonian patients at the CNS between January
and September 2019, and if they agreed to participate. Exclusion
criteria were the inability to adopt a standing position and/or
to walk 3m, postural instability compromising patient safety
during the assessment, and the presence of cognitive deficits
preventing understanding of the test instructions (according to
a physiotherapist’s best judgment). The study was undertaken
with the understanding and written consent of each participant,
with the approval from the CNS Ethics Committee (ref. 10/19),
and in compliance with national legislation and the Declaration
of Helsinki. Participants were required to agree to all aspects of
the study and were able to leave the study at any time.
Therapeutic Intervention
The specialized multidisciplinary program combined
pharmacological and non-pharmacological therapies, including
up to 20 h per week of individually tailored neurorehabilitation
sessions of physiotherapy, occupational therapy, speech therapy,
and cognitive training, according to the patient’s needs and
rehabilitation goals. All rehabilitation sessions had a duration of
50 min.
The physiotherapy sessions aim to optimize independence,
safety, and well-being, through movement rehabilitation,
maximization of functionality, and minimization of secondary
complications. The sessions focused on physical capacity
training, gait, mobility, balance, sensorimotor coordination,
and development, as well as teaching the patient and the usual
caregivers adaptive strategies to enhance functionality.
Clinical Assessment Protocol
Patients were assessed in ON-state medication, by a trained
health professional from each area, 48 h following admission and
before discharge. The following parameters were collected:
• Demographic and clinical data;
• Disease severity: Movement Disorder Society–Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS) total score
and score from each sub-section (8), Hoehn and Yahr scale
(8, 9), and Clinical and Patient Global Impression (CGI and
PGI, respectively) of Severity and Change; (10)
• Motor function: The Timed Up and Go (TUG) test with
and without a cognitive and manual dual-task (5, 11, 12),
Mini-BESTest (5, 13, 14), Five times Sit-to-Stand test (5 STS)
(15, 16), and Schwab and England scale (17).
Analysis of Kinematic Data
Kinematic gait parameters were collected during the supervised
motor assessments and for 3 days at the end of each assessment,
in a free-living (FL) context. Each participant wore a single tri-
axial accelerometer-based body-worn monitor (Axivity AX3) on
their lower back (L5), programmed to capture raw data at 100Hz
with a dynamic range of ±8 g. Each subject performed two trials
of each assessment, on each visit, and wore the AX3 for 3 days
after each assessment.
In the supervised motor assessment, the physiotherapist used
a mobile application to mark the start and end of each trial,
which was synced with the AX3 internal clock. Departing from
the segmentation of test trials provided by the application, we
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manually adjusted the start and end of each test to match with
the exact start and end of the movement and removed reported
periods of pause. To extract meaningful data from the raw
accelerometer signal, we started by resampling data to 100Hz
using linear interpolation, to mitigate known fluctuations of
the sample rate (18). Afterward, offset was removed as well as
machine noise using a second-order Butterworth low pass filter
of 17Hz (19). We focused the kinematic gait analysis in the study
of spatiotemporal gait parameters. To extract gait parameters,
the process was divided into two steps. First, we identified
the walking bouts as the 2-s moving windows where summed
standard deviations of tri-axial accelerations were above 0.1 (20).
Then, an algorithm to detect initial contact (IC)/final contact
(FC) points was applied, from which we calculated the gait
parameters (21). A concurrent validity analysis of the reported
number of steps (by the physiotherapist observing the trial)
and the automatic detection revealed an intra-class correlation
above 0.85.
In the FL context, where walking bouts are not previously
annotated, a conservative approach was followed, meaning that
high precision was sought (seeking that all detected bouts are
indeed bouts), even if at the cost of lower recall (i.e., not all
bouts are detected). Pre-processing of FL raw data followed a
similar approach as the controlled assessment (resample and
filtering). To improve walking bout detection in FL, we estimated
an optimized scale of the Gaussian continuous wavelet transform
(22) (“gaus2”) and considered only the segments with a duration
above 5 s and at least five detected ICs. Additionally, the first
and last detected steps of each bout were trimmed off, given
their specific transition characteristics. All remaining bouts (and
steps) were subjected to extraction of parameters. An average per
subject of 285.3 (SD = 175.2, min = 17, max = 622) walking
bouts were extracted at the period of admission, and an average
of 270.4 (SD = 129.0, min = 32, max = 647) were detected at
the period of discharge, in the 3-day period. Gait parameters
were calculated from the detected bouts as in the supervised
motor assessment (21). Following previously published evidence
in FL assessment, gait parameters were categorized in bouts
from 5 to 15 s, 15 to 30 s, 30 to 60 s, and longer than 60 s (21).
Our implementation of the extraction of gait parameters from
walking bouts is available and open-sourced (https://github.com/
Gustavo-SF/gait_extractor).
Statistical Analysis
Descriptive statistics were used for demographic, clinical, and
therapeutic data. Continuous outcomes were defined as change
from baseline for all the previously mentioned outcomemeasures
and presented as a mean± standard deviation (SD).
Our main goal was to explore the best predictors of changes
in TUG (the gold standard for evaluating FM in PD). To do
this, stepwise multiple linear regression analyses were performed
using different independent variables (clinical measures, gait
parameter assessment during the 10-m walk test, and FL gait
parameters analyzed in bouts longer than 60 s). To validate the
analysis, the normal distribution of residuals and the absence of
multicollinearity were ascertained.
Only the outcome measures able to detect an effect of the
intervention were used in the main analysis. This required an
assessment, before our main analysis, of the existence of an
intervention effect and the ability of the included outcome
measures to detect it. We started by studying normality, using the
Kolmogorov–Smirnov and the Shapiro–Wilk tests, and applying
the paired sample T-test and the Wilcoxon S-R test to each
parameter to analyze the effects of the program (statistical
significance was set at p < 0.05). Cohen’s d was employed as
a measure of effect size to assess small (0.20–0.49), medium
(0.50–0.80), and large (>0.80) effects (23).
We also performed some exploratory analysis to better
understand how the outcome measures, selected as best
predictors of FM changes, behave if used as the primary outcome
in a future study. Power analysis and sample size calculations
were performed using G∗Power software, to understand how
many participants would be needed to enable statistically
significant results (80% power) if the TUG test or one of the
outcome measures able to detect at least a small effect size were
used as the primary outcome in a clinical study. A significance
level of α = 0.05 and a power = 1 – β = 0.80 were assumed. To
explore the variability of the different gait parameters, a power
analysis assuming 10, 20, and 30% of change from baseline and
using the mean SD of change from baseline was calculated for
each parameter. The choice of the 30% magnitude of effect was
based on the minimal clinically important difference (MCID)
reported for the TUG test, the recommended measurement tool
for assessing FM in PD. It also used a 20% magnitude of effect,
based on MCID reported for spatial asymmetry in a previous
study evaluating the effect of rehabilitation training on PD
patients’ gait parameters (25.76%) (24).
Additionally, and also as an exploratory analysis, we applied
paired sample t-test and the Wilcoxon S-R test to the different
bout lengths of FL assessment to investigate how the length of
the bout contributes to the existence of a statistically significant
difference between admission and the end of the program
(significance was achieved with a p-value < 0.05).
RESULTS
Cohort Demographic and Clinical Data
Of the 54 PD patients who engaged in a CNS specialized
multidisciplinary program between January and September 2019,
a total of 24 participants were included in this study. The reasons
for exclusion were lack of collaboration/missing data (27.8%, n
= 15), motor inability to perform the assessments (18.5%, n =
10), and the presence of cognitive impairment and behavioral
disturbances (9.3%, n= 5). Eight patients did not perform the FL
assessment due to behavioral disturbances and refusal of the belt
that supports the trunk sensor. Some of the included patients did
not fulfill all the clinical assessment battery due to fatigue and lack
of collaboration. The mean age of the participants was 73.0± 8.0
years, and 66.7% (n = 16) were men. At admission, the average
disease duration was 8.0 ± 5.1 years, with a mean Hoehn and
Yahr stage of 2.3 ± 0.9 and a mean MDS-UPDRS motor score of
39.4± 12.8. All patients were under antiparkinsonian treatment,
and 50% (n= 12) had motor fluctuations.
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TABLE 1 | Demographical and clinical characteristics of the sample.
Demographic features (n = 24)
Age (Mean, SD) 73.04 ± 8.00
Male sex [% (n)] 66.67% (16)
Body mass index (BMI) (Mean, SD) 25.79 ± 3.90
Time since diagnosis (Mean, SD) 8.04 ± 5.10
Presence of motor fluctuations [% (n)] 50% (12)
Clinical data [Mean (SD), (Range)]
Admission Discharge Change p-value
MDS-UPDRS I (range 0–52; n = 19; ↓) 13.95 ± 7.09 8.25 ± 4.90 −5.53 ± 6.81 (39.6%) 0.002
MDS-UPDRS II (range 0–52; n = 19; ↓) 17.18 ± 9.24 12.65 ± 7.04 −4.95 ± 10.02 (28.8%) 0.045
MDS-UPDRS III (range, 0–132; n = 19; ↓) 39.36 ± 12.77 32.20 ± 12.22 −8.52 ± 9.92 (21.7%) 0.001
MDS-UPDRS IV (range 0–24; n = 19; ↓) 1.95 ± 2.82 1.35 ± 2.16 −0.21 ± 2.53 (10.8%) 0.721
MDS-UPDRS Total (range 0–260; n = 19; ↓) 72.45 ± 25.75 54.45 ± 20.50 −19.26 ± 22.18 (26.6%) 0.001
Hoehn and Yahr stage (range 1–5; n = 24; ↓) 2.30 ± 0.93 2.35 ± 0.71 0.09 ± 0.68 (3.9%) 0.540
Schwab and England (range 0–100; n = 24; ↑) 73.75 ± 16.37 75.83 ± 15.86 2.08 ± 8.33 (2.8%) 0.225
TUG Normal (n = 24; ↓) 13.36 ± 7.27 11.68 ± 4.75 −1.69 ± 6.90 (12.7%) 0.243
TUG DT Cognitive (n = 23; ↓) 17.22 ± 10.42 14.10 ± 7.29 −2.80 ± 8.91 (16.3%) 0.146
TUG DT Manual (n = 19; ↓) 12.80±5.21 11.37±4.35 −0.92 ± 8.69 (7.2%) 0.417
Mini-best (range 0–28; n = 19; ↑) 20.19±3.97 20.70±4.59 0.63 ± 3.25 (3.1%) 0.408
5 Sit-to-Stand Normal (n = 22; ↓) 19.36 ± 6.99 14.29 ± 5.24 −4.31 ± 2.94 (22.3%) 0.000
5 Sit-to-Stand Fast (n = 22; ↓) 17.56 ± 4.91 13.25 ± 5.19 −5.07 ± 3.48 (28.9%) 0.000
Severity (Baseline) Change (Discharge)
Clinical Global Impression (n = 24; ↓) 4.0 ± 0.83 2.83 ± 0.82
Patient Global Impression (n = 24; ↓) 3.91 ± 1.02 2.50 ± 0.86
↑ - a higher score means an improvement, ↓ - a lower score means an improvement. The paired-samples T-test and the Wilcoxon S-R tests were applied to investigate the existence
of a statistically significant difference between admission and the end of the program. Significance was achieved with a p-value < 0.05. Bold values is to highlight the outcomes that
reached statistical significance.
Patients’ demographic and clinical characteristics at
admission and discharge are summarized in Table 1. Table 2
summarizes the changes in gait parameter values in both
assessment conditions.
All the clinical and gait parameters from the supervised
assessment showed an improvement, having reached statistical
significance (p ≤ 0.05) in the MDS-UPDRS parts I, II, III, and
total score; in the 5 STS test; and the following gait parameters:
gait velocity, stride and step velocity, step length, and swing
time asymmetry (Tables 1, 2). The improvement in the TUG test
did not reach statistical significance, contrary to gait velocity,
stride and step velocity, step length, and swing time asymmetry
measured during the test. In FL conditions, an improvement was
detected when the analysis was made using bouts of at least 30 s.
Specifically, the following gait parameters have reached statistical
significance (p ≤ 0.05): cadence, step time, stance time, swing
time, and double support time when data was analyzed in bouts
of 30–60 s and stance, swing, and double support phases when
bouts of more than 60 s were used in the analysis (Table 2 and
Appendix 1).
Prediction of FM Changes
The stepwise multivariate linear regression analysis, between
TUG (dependent variable) and the clinical outcome measures
able to detect an effect, indicated the TUG Cognitive as the
best variable to predict TUG changes (adjusted R2 = 0.72). The
same analysis using supervised and FL kinematic gait parameters
as independent variables identified step length (adjusted R2 =
0.53) and step time asymmetry (adjusted R2 = 0.51) as the
best predictors of TUG changes for each assessment condition
(Table 3).
Responsiveness to Intervention
The TUG test was able to detect a small effect size (d =−0.24) of
the intervention (Appendix 2).
From the supervised assessment, the outcome measures able
to detect a large effect size were the STS Normal (d=−1.46) and
Fast (d =−1.47) and the MDS-UPDRS total score (d =−0.87).
From the FL assessment, the outcome parameters with higher
sensitivity to the intervention were stance time asymmetry (d =
−0.38), stride length (d = 0.37), double support time variability
(d =−0.37), and step length (d = 0.36).
Sample Size Calculation
A power analysis was performed to understand how many
participants would be needed to enable statistically significant
results (80% power), if the TUG test or one of the outcome
measures able to detect at least a small effect size was used as


































TABLE 2 | Admission (i.e., baseline) and change from baseline values (i.e., mean post-pre assessment difference and respective percentage value) of gait parameters in the supervised and free-living assessments.
Gait parameters supervised
assessment
Supervised assessment Free-living assessment
TUG normal 10-meter walk test Bouts longer than 60 s
Admission Change from
baseline
p-value Admission Change from
baseline
p-value Admission Change from
baseline
p-value
Gait velocity (m/s) 0.71 ± 0.19 0.06 ± 0.13
(8.5%)
0.037 0.82 ± 0.21 0.05 ± 0.18
(6.1%)
0.188 0.59 ± 0.14 0.04 ± 0.13
(6.8%)
0.209
Cadence (steps/min) 118.77 ± 12.00 1.94 ± 13.02
(1.6%)
0.472 119.92 ± 13.72 3.66 ± 12.95
(3.1%)
0.180 104.93 ± 10.33 −0.92 ± 9.17
(0.9%)
0.695
Stride length (m) 0.78 ± 0.18 0.06 ± 0.14
(7.7%)
0.057 0.89 ± 0.20 0.04 ± 0.17
(4.5%)
0.204 0.69 ± 0.16 0.05 ± 0.13
(7.2%)
0.160
Stride velocity (m/s) 0.71 ± 0.19 0.06 ± 0.13
(8.5%)
0.033 0.82 ± 0.21 0.05 ± 0.18
(6.1%)
0.225 0.59 ± 0.14 0.04 ± 0.13
(6.8%)
0.202
Step length (m) 0.39 ± 0.09 0.03 ± 0.07
(7.7%)
0.049 0.45 ± 0.10 0.02 ± 0.08
(4.4%)
0.230 0.34 ± 0.08 0.02 ± 0.06
(5.9%)
0.171
Step velocity (m/s) 0.72 ± 0.19 0.06 ± 0.13
(8.3%)
0.037 0.82 ± 0.21 0.05 ± 0.18
(6.1%)
0.182 0.60 ± 0.14 0.04 ± 0.13
(6.7%)
0.220
Stance phase (% of gait cycle) 75.26±1.36 −0.11 ± 1.35
(0.2%)
0.708 75.35 ± 0.49 −0.18 ± 1.32
(0.2%)
0.514 75.11 ± 0.55 0.20 ± 0.36
(0.3%)
0.047
Swing phase (% of gait cycle) 24.74 ± 1.36 0.11 ± 1.35
(0.5%)
0.708 24.65 ± 0.49 0.18 ± 1.32
(0.7%)
0.514 24.89 ± 0.55 −0.20 ± 0.36
(0.8%)
0.047
Double support phase (% of gait cycle) 25.33 ± 1.33 −0.13 ± 1.36
(0.5%)
0.643 25.34 ± 0.51 −0.19 ± 1.27
(0.8%)
0.476 25.11 ± 0.54 0.19 ± 0.36
(0.8%)
0.050
Step time (seconds) 0.56 ± 0.06 −0.02 ± 0.06
(3.6%)
0.893 0.55 ± 0.07 −0.01 ± 0.06
(1.8%)
0.525 0.60 ± 0.06 0.002 ± 0.06
(0.3%)
0.896
Stance time (seconds) 0.84 ± 0.09 −0.01 ± 0.09
(1.2%)
0.800 0.83 ± 0.10 −0.01 ± 0.09
(1.2%)
0.589 0.90 ± 0.09 0.004 ± 0.09
(0.4%)
0.845
Swing time (seconds) 0.28 ± 0.04 0.002 ± 0.04
(0.7%)
0.828 0.27 ± 0.03 −0.001 ± 0.03
(3.7%)
0.902 0.30 ± 0.03 −0.001 ± 0.03
(0.3%)
0.930
Double support time (seconds) 0.28 ± 0.03 −0.004 ± 0.03
(1.4%)
0.561 0.28 ± 0.03 −0.004 ± 0.03
(1.4%)
0.916 0.30 ± 0.03 0.004 ± 0.03
(1.3%)
0.583
Stride time variability (% CV) 0.07 ± 0.04 −0.004 ± 0.04
(5.7%)
0.636 0.04 ± 0.02 −0.001 ± 0.03
(2.5%)
0.880 0.12 ± 0.03 −0.01 ± 0.04
(8.3%)
0.393
Step length variability (% CV) 0.05 ± 0.02 −0.003 ± 0.03
(6%)
0.516 0.03 ± 0.01 0.004 ± 0.02
(13.3%)
0.260 0.06 ± 0.01 0.003 ± 0.02 (5%) 0.446
Step time variability (% CV) 0.05 ± 0.03 −0.002 ± 0.03
(4%)
0.730 0.03 ± 0.02 −0.0004 ± 0.02
(1.3%)
0.930 0.09 ± 0.02 −0.01 ± 0.03
(11.1%)
0.210
Step velocity variability (% CV) 0.11 ± 0.04 −0.008 ± 0.04
(7.3%)
0.352 0.06 ± 0.02 0.01 ± 0.04
(16.7%)
0.163 0.13 ± 0.03 0.004 ± 0.03
(3.1%)
0.657
Stance time variability (% CV) 0.06 ± 0.03 −0.005 ± 0.03
(8.3%)
0.384 0.03 ± 0.02 −0.002 ± 0.02
(6.7%)






















































































TABLE 2 | Continued
Gait parameters supervised
assessment
Supervised assessment Free-living assessment
TUG normal 10-meter walk test Bouts longer than 60 s
Admission Change from
baseline
p-value Admission Change from
baseline
p-value Admission Change from
baseline
p-value
Swing time variability (% CV) 0.03 ± 0.02 −0.006 ± 0.02
(20%)
0.884 0.02 ± 0.01 0.001 ± 0.02
(20%)
0.862 0.05 ± 0.02 −0.01 ± 0.02
(20%)
0.216
Double support variability (% CV) 0.03 ± 0.02 −0.003 ± 0.02
(10%)
0.455 0.02 ± 0.01 0.00002 ± 0.01
(0.1%)
0.994 0.05 ± 0.02 −0.01 ± 0.02
(20%)
0.163
Stride time asymmetry (% CV) 0.01 ± 0.01 0.002 ± 0.02
(20%)
0.959 0.01 ± 0.01 −0.001 ± 0.01
(10%)
0.584 0.01 ± 0.004 −0.001 ± 0.01
(1%)
0.300
Step time asymmetry (% CV) 0.02 ± 0.02 0.005 ± 0.02
(25%)
0.262 0.03 ± 0.02 0.003 ± 0.02
(10%)
0.496 0.03 ± 0.02 −0.01 ± 0.02
(33.3%)
0.318
Stance time asymmetry (% CV) 0.02 ± 0.02 −0.003 ± 0.02
(15%)
0.622 0.02 ± 0.02 −0.003 ± 0.02
(15%)
0.420 0.02 ± 0.01 −0.01 ± 0.02
(50%)
0.153
Swing time asymmetry (% CV) 0.02 ± 0.01 0.008 ± 0.02
(40%)
0.036 0.02 ± 0.01 −0.003 ± 0.02
(15%)
0.423 0.02 ± 0.01 −0.01 ± 0.02
(50%)
0.195
Step length asymmetry (% CV) 0.03 ± 0.02 −0.002 ± 0.02
(6.7%)
0.605 0.02 ± 0.02 0.0002 ± 0.02
(1%)
0.959 0.02 ± 0.01 −0.002 ± 0.01
(10%)
0.504
The paired-samples T-test and the Wilcoxon S-R tests were applied for each parameter to investigate the existence of a statistically significant difference between admission and the end of the program (statistical significance was
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TABLE 3 | Stepwise multiple linear regression analysis with TUG as a dependent variable and (1) the clinical outcome measures, (2) gait parameters assessed during the
10-meter walk test, in supervised conditions, (3) gait parameters assessed in free-living conditions and analyzed in bouts longer than 60 s, as independent variables.
Dependent variable: TUG
change from baseline
























0.55 0.51 0.55 16.79 0.001 104.88 0.74 1.000
a primary outcome in a clinical study. Appendix 2 summarizes
the sample size calculations assuming 10, 20, and 30% change
from baseline.
DISCUSSION
Although this study was not designed to conclude on efficacy,
the results obtained suggest an overall improvement (Tables 1,
2). This enables us to identify the best predictors of FM changes
when PD patients are submitted to a specializedmultidisciplinary
program. It also enables performing other exploratory analyses to
better understand how the outcome measures behave if used as
primary outcomes in future studies.
From the pool of outcome measures able to detect at least a
small effect size of the intervention, those identified as the best
predictors of TUG changes were the TUG Cognitive, step length,
and step time asymmetry.
Clinical Assessment
The TUG Cognitive test was the clinical parameter with the best
ability to predict TUG changes. This can be explained because the
TUG Cognitive is a modified version of the TUG (i.e., it adds a
cognitive task to the motor task) (25, 26). Since daily activities
frequently require motor and cognitive tasks to be carried out
simultaneously, this version of the test may give a more realistic
perspective of the patients’ FM. However, as it is only a modified
version of the same test, some major limitations remain (e.g., it is
limited to patients without significant postural instability and is
subject to learning effects).
The Mini-BESTest test was not sensitive to the intervention,
and the observed differences were not statistically significant.
However, this is a very complete clinical test that includes the
assessment of static and dynamic balance (i.e., biomechanical
constraints, verticality/stability limits, anticipatory postural
adjustments, postural responses, sensory orientation, and
stability in gait) and the TUG Cognitive test itself (5, 13, 14).
Although not formally validated to measure FM, this instrument
provides a more complete approach to the three anchors of the
concept, i.e., gait, balance, and postural transitions (5, 13, 14).
We believe that future studies should clarify the Mini-BESTest’s
suitability to assess FM changes.
Clinical vs. Kinematic Assessment
Our results identified step length and step time asymmetry as
the gait parameters with the best ability to predict TUG (and
FM) changes, in supervised and FL conditions, respectively.
Compared with the TUG, both showed higher responsiveness
to change.
FM is a major source of disability for PD patients and
requires an individualized and complex management approach
that strongly depends on the information about the actual state of
the patients in their daily lives (1). Although the TUG remains the
gold standard for assessing PD FM, as is the case for all traditional
clinical scales, it presents some limitations that can be overcome
by the use of TOMs (27).
To optimize the accuracy of clinical evaluation, evidence
suggests that patients should focus on the goal of the task
asked and not on the movement required to achieve it. This is
hampered when a reassessment using the TUG test takes place
after a multidisciplinary program. During the physiotherapy
sessions of the program, patients usually learn safety strategies to
apply during walking and postural transitions that require being
focused on the movement while doing it. Many of these strategies
are applied during the TUG test, thereby hindering its ability to
detect an improvement in patients’ FM (27).
There is increasing evidence that TOMs may improve the
sensitivity, accuracy, reproducibility, and feasibility of data
capture, detecting improvements that the clinical tests are not
able to find (6). Previous studies reported a greater sensitivity of
TOMs, over the traditional clinical scales, in differentiating the
gait and turning of PD patients from healthy controls (27).
The use of outcome measures of higher sensitivity and
accuracy, which can predict TUG changes (step length and step
time asymmetry), may help obtain amore complete and objective
evaluation of patients’ FM limitations and thereby favoring more
personalized clinical decision making (6, 28). In the research
field, the use of standardized outcome measures, with high
responsiveness to change and low variability, not only enables
better interpretation and discussion of research findings but
also avoids unnecessary increases in complexity, duration, and
financial expenses of studies (6).
Despite the benefits associated with the use of TOMs
for assessing FM, from our experience, they also have some
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limitations. The currently available sensors, although smaller and
lighter, remain too intrusive, leading patients to reject their use.
Also, in PD patients with behavioral changes, the use of sensors
may not be possible. One of the patients was excluded from the FL
analysis, after having thrown away the sensors during an episode
of delirium.
Supervised vs. Free-Living Assessment
According to our results, the responsiveness of the outcomes and
their ability to predict TUG changes differ depending on the type
of assessment.
There is a growing awareness that, depending on the
assessment conditions, the results related to gait and postural
transitions can differ substantially, with a weak association
between the results in both scenarios having been reported (28,
29). Many factors can contribute to these differences: (1) the
clear and standardized environment in supervised assessment, in
the absence of distractions, emphasizes a measure of someone’s
best, rather than their usual performance; (2) FL conditions,
with narrow corridors, variable lighting, obstacles, etc., forces
continuous gait adaptations, inducing large variability and
asymmetry in walking patterns; (3) movements in a supervised
assessment are triggered by instruction, while FL movements
are usually self-initiated, goal-directed, and embedded in a rich
behavioral environment; and (4) patients frequently improve
their performance when they know that they are being evaluated
(21, 28, 29).
In the FL context, gait parameters, and therefore FM, may
be influenced not only by physical characteristics but also by
ongoing environmental and cognitive challenges (29). Variability
and asymmetry-related parameters are especially sensitive to
behavioral and environmental factors, better reflecting patients’
interactionwith the context and their ability to adapt gait patterns
(28, 29). We hypothesize that this may be one of the causes
of step time asymmetry identified as the FL kinematic gait
parameter, which better predicts TUG changes. Although it has
only captured a small effect size of the intervention, having a
high ecological validity, FL step time asymmetry seems to provide
a more realistic picture of the impact of the disease in PD FM,
whereby even small changes should be valued (27).
Length of Walking Bouts
We performed an exploratory analysis to understand how FL
gait parameters behave when different bout lengths were used in
the analysis. According to our results, there appears to be a link
between the ability to capture an improvement and the length of
the bout. The longer the walking bouts, the higher the velocity
and length of stride/step and the lower the cadence, variability,
and asymmetry.
A previous study exploring the impact of environment and
bout length in PD patients’ gait reached similar conclusions, i.e.,
the longer the bouts, the higher the increase in step velocity, step
length and swing time variability and the lower the variability and
asymmetry of gait. The authors also reported that the parameters
analyzed in longer bouts were more similar to those measured in
a supervised environment (21).
Walking bout length is influenced by the type of environment
and activity patients are engaged in (21). Currently, the most
suitable length of walking bouts used in FL analysis is not
established (21). The majority of studies investigating gait
characteristics in FL conditions use bouts longer than 60 s.
However, it has been reported that PD patients in FL conditions
more often perform a large number of very short bouts (≤10 s)
than prolonged bouts (21). According to the literature, bouts of
30–60 s usually represent indoor activities, while bouts > 120 s
correspond to walking outdoors. Only bouts with at least 30–60 s
were able to discriminate PD patients from healthy controls (21).
Limitations
This study presents two major limitations: a small sample size
(n = 24) and high heterogeneity in the included population.
We believe that these aspects may overestimate the variability of
the measurement tools, influencing the power calculations. We
expect that future studies with a large and less heterogeneous
population will need a smaller sample size. As an open non-
controlled study, we hypothesize that in future larger, controlled
trials, the detected effect size will be smaller. However, since this
was not an efficacy study (due to the absence of a control group)
and an improvement was observed, despite these limitations, we
believe that our results are informative and important for the PD
field. Also, we believe that the use of broad inclusion criteria in
this study not only did not interfere with its aims but also better
mimics the real scenario of the intervention and assessments,
increasing its external validity. Tominimize the impact, the study
was conducted in a single tertiary care center.
According to our results, the TUG test did not achieve
a statistically significant improvement. However, some of the
gait parameters (including step length) not only reached a
statistically significant result but also showed a higher sensitivity
to change. Since all other results point to an improvement at
the end of the program, we believe that this difference may
be explained by the greater accuracy and sensitivity to change
of TOMs when compared to the traditional clinical scales. A
previous study has already highlighted this potential problem,
highlighting that the validation of TOMs is often based on
their correlation with validated clinical measures and that results
may be undesirable, due to the superior capacity of TOMs for
capturing the phenomena of interest (30).
CONCLUSION
Although we cannot attribute the observed improvements to
the specialized multidisciplinary program, our results suggest a
methodological approach for identifying outcome measures to
assess FM changes, in response to a therapeutic intervention.
From all the outcome measures included in the study, only
the TUG Cognitive, step length, and FL step time asymmetry
were identified as having the ability to predict TUG changes.
The kinematic parameters seem to present higher responsiveness
to change when compared with the traditional clinical tests.
According to our results, supported by published evidence,
the longer the bouts, the higher the sensitivity of detecting
an improvement.
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Our results support the use of kinematic assessments in
evaluating the effect of multidisciplinary interventions in PD FM.
The FL step time asymmetry seems a very promising outcome
measure to assess FM in PD. Nevertheless, there are some
aspects of FL assessments that need to be improved, such as
establishing the best data collection protocol and developing less
intrusive sensors.
To improve the interpretation of results of responsiveness
to change in a complex and fluctuating disease such as PD,
it is necessary to clarify the variation of gait parameters
in the absence of pharmacological and non-pharmacological
therapeutic interventions. This requires repeating the assessment
protocol in ON- and OFF-state medication and several
times during a short period, thereby clarifying the effect of
pharmacological interventions, permitting an understanding of
the impact of motor fluctuations andminimizing the interference
of disease progression. More studies are also needed to explore
the cut-off points from which FM is considered to be affected
and the smallest amount of change, in the identified parameters,
considered important by the patient or clinician (i.e., the minimal
clinically important difference).
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by CNS Ethics Committee. The patients/participants
provided their written informed consent to participate in
this study. Written informed consent was obtained from the
individual(s) for the publication of any potentially identifiable
images or data included in this article.
AUTHOR CONTRIBUTIONS
RB-M and JF contributed to the conception and design of
the study. The CNS physiotherapy study group contributed to
the participants’ recruitment and assessments. RB-M performed
the assessments and performed the statistical analysis. DB, GF,
and TG analyzed kinematic data. RB-M and JF drafted the
manuscript. All authors contributed to manuscript revision and
read and approved the submitted version.
FUNDING
The authors would like to acknowledge the support of Fundação
para a Ciência e a Tecnologia (FCT) (SFRH/BD/120773/2016




Daniela Guerreiro, Verónica Caniça, Francisco Queimado, Pedro
Nunes, Alexandra Saúde, Laura Antunes, Joana Alves, Beatriz
Santos, Inês Lousada, Maria A. Patriarca, Patrícia Costa, Raquel
Nunes e Susana Dias.
SUPPLEMENTARY MATERIAL




1. Bouça-Machado R, Maetzler W, Ferreira JJ. What is functional mobility
applied to Parkinson’s disease? J Parkinsons Dis. (2018) 8:121–30.
doi: 10.3233/JPD-171233
2. Bouça-Machado R, Duarte GS, Patriarca M, Castro Caldas A, Alarcão J,
Fernandes RM, et al. measurement instruments to assess functional mobility
in Parkinson’s disease: a systematic review. Movement Disord Clin Pract.
(2020) 7:129–39. doi: 10.1002/mdc3.12874
3. Bhidayasiri R, Martinez-Martin P. Clinical assessments in Parkinson’s disease.
Int Rev Neurobiol. (2017) 132:129–82. doi: 10.1016/bs.irn.2017.01.001
4. Verheyden G, Kampshoff CS, Burnett ME, Cashell J, Martinelli L, Nicholas
A, et al. Psychometric properties of 3 functional mobility tests for people
with Parkinson disease. Phys Ther. (2014) 94:230–9. doi: 10.2522/ptj.201
30141
5. Bloem BR, Marinus J, Almeida Q, Dibble L, Nieuwboer A, Post B, et al.
Measurement instruments to assess posture, gait, and balance in Parkinson’s
disease: critique and recommendations. Mov Disord. (2016) 31:1342–55.
doi: 10.1002/mds.26572
6. Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, et al.
Technology in Parkinson disease: challenges and opportunities. Mov Disord.
(2016) 31:1272–82. doi: 10.1002/mds.26642
7. Muro-de-la-Herran A, García-Zapirain B, Méndez-Zorrilla A. Gait analysis
methods: an overview of wearable and non-wearable systems, highlighting
clinical applications. Sensors. (2014) 14:3362–94. doi: 10.3390/s140203362
8. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-
Martin P, et al. Movement Disorder Society-sponsored revision of
the unified Parkinson’s disease rating scale (MDS-UPDRS): scale
presentation and clinimetric testing results. Mov Disord. (2008) 23:2129–70.
doi: 10.1002/mds.22340
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality.
Neurology. (1967) 17:427–42. doi: 10.1212/WNL.17.5.427
10. Martínez-Martín P, Rojo-Abuin JM, Rodríguez-Violante M, Serrano-Dueñas
M, Garretto N, Martínez-Castrillo JC, et al. Analysis of four scales for global
severity evaluation in Parkinson’s disease. NPJ Park Dis. (2016) 2:16007.
doi: 10.1038/npjparkd.2016.7
11. Podsiadlo D, Richardson S. The timed “up & go”: a test of basic functional
mobility for frail elderly persons. J Am Geriatr Soc. (1991) 39:142–8.
doi: 10.1111/j.1532-5415.1991.tb01616.x
12. Morris S, Morris ME, Iansek R. Reliability of measurements obtained with
the timed ‘up, & go’ test in people with Parkinson disease. Phys Ther. (2001)
81:810–8. doi: 10.1093/ptj/81.2.810
13. Franchignoni F, Horak F, Godi M, Nardone A, Giordano A. Using
psychometric techniques to improve the balance evaluation systems test:
the mini-BESTest. J Rehabil Med. (2013) 42:323–31. doi: 10.2340/165019
77-0537
14. Leddy AL, Crowner BE, Earhart GM. Utility of the mini-BESTest,
BESTest, and BESTest sections for balance assessments in individuals
with Parkinson disease. J Neurol Phys Ther. (2011) 35:90–7.
doi: 10.1097/NPT.0b013e31821a620c
Frontiers in Neurology | www.frontiersin.org 9 March 2021 | Volume 12 | Article 637620
Bouça-Machado et al. Outcomes for Assessing PD FM
15. Mayhew T, Rothstein J. Measurement of muscle performance with
instruments. Percept Mot Skills. (1995) 80:163–6. doi: 10.2466/pms.1995.
80.1.163
16. Duncan RP, Leddy AL, Earhart GM. Five times sit-to-stand test performance
in Parkinson’s disease. Arch Phys Med Rehabil. (2011) 92:1431–6.
doi: 10.1016/j.apmr.2011.04.008
17. Bjornestad A, Tysnes OB, Larsen JP, Alves G. Reliability of three disability
scales for detection of independence loss in Parkinson’s disease. Parkinsons
Dis. (2016) 2016:1941034. doi: 10.1155/2016/1941034
18. Doherty A, Jackson D, Hammerla N, Plötz T, Olivier P, Granat MH, et al.
Large scale population assessment of physical activity using wrist worn
accelerometers: the UK biobank study. PLoS ONE. (2017) 12:e0169649.
doi: 10.1371/journal.pone.0169649
19. Hickey A, Del Din S, Rochester L, Godfrey A. Detecting free-living steps and
walking bouts: validating an algorithm for macro gait analysis. Physiol Meas.
(2017) 38:N1–N15. doi: 10.1088/1361-6579/38/1/N1
20. Lyons GM, Culhane KM, Hilton D, Grace PA, Lyons D. A description
of an accelerometer-based mobility monitoring technique. Med
Eng Phys. (2005) 27:497–504. doi: 10.1016/j.medengphy.2004.
11.006
21. Del Din S, Godfrey A, Galna B, Lord S, Rochester L. Free-living gait
characteristics in ageing and Parkinson’s disease: impact of environment
and ambulatory bout length. J Neuroeng Rehabil. (2016) 13:46.
doi: 10.1186/s12984-016-0154-5
22. Pham MH, Elshehabi M, Haertner L, Del Din S, Srulijes K, Heger T,
et al. Validation of a step detection algorithm during straight walking and
turning in patients with Parkinson’s disease and older adults using an
inertial measurement unit at the lower back. Front Neurol. (2017) 8:1–9.
doi: 10.3389/fneur.2017.00457
23. Aron, A. Statistics for Psychology (2003).
24. Serrao M, Chini G, Caramanico G, Bartolo M, Castiglia SF,
Ranavolo A, et al. Prediction of responsiveness of gait variables to
rehabilitation training in Parkinson’s disease. Front Neurol. (2019) 10:826.
doi: 10.3389/fneur.2019.00826
25. Campbell CM, Rowse JL, Ciol MA, Shumway-cook A. The effect of
cognitive demand on timed up and go performance in older adults
with and without Parkinson disease. Neurol Rep. (2003) 27:2–7.
doi: 10.1097/01253086-200327010-00002
26. Hofheinz M, Schusterschitz C. Dual task interference in estimating
the risk of falls and measuring change: a comparative, psychometric
study of four measurements. Clin Rehabil. (2010) 24:831–42.
doi: 10.1177/0269215510367993
27. Del Din S, Godfrey A, Mazzà C, Lord S, Rochester L. Free-living monitoring
of Parkinson’s disease: lessons from the field.MovDisord. (2016) 31:1293–313.
doi: 10.1002/mds.26718
28. Warmerdam E, Hausdorff JM, Atrsaei A, Zhou Y, Mirelman A, Aminian K,
et al. Long-term unsupervised mobility assessment in movement disorders.
Lancet Neurol. (2020) 19:462–70. doi: 10.1016/S1474-4422(19)30397-7
29. Rispens SM, Van Dieën JH, Van Schooten KS, Lizama LE, Daffertshofer A,
Beek PJ, et al. Fall-related gait characteristics on the treadmill and in daily life.
J Neuroeng Rehabil. (2016) 13:12. doi: 10.1186/s12984-016-0118-9
30. Artusi CA, Mishra M, Latimer P, Vizcarra JA, Lopiano L, Maetzler W,
et al. Integration of technology-based outcome measures in clinical trials of
Parkinson and other neurodegenerative diseases. Park Relat Disord. (2018)
46:S53–6. doi: 10.1016/j.parkreldis.2017.07.022
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Bouça-Machado, Branco, Fonseca, Fernandes, Abreu, Guerreiro,
Ferreira and The CNS Physiotherapy Study Group. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Neurology | www.frontiersin.org 10 March 2021 | Volume 12 | Article 637620
